Four oral GLP-1R products in Phase III trials as race intensifies

The popularity of GLP-1 receptor (GLP-1R) subcutaneous treatments for obesity has proved the demand for the drugs, but the lack of oral alternatives represents a significant (and profitable) gap, according to an analyst at GlobalData.